US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

Whitepaper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

Merger and Acquisitions

White Paper

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 2

Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

White Paper

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 1

The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...

PBMs Pharma Benefit Manager

White Paper

Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs

This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White Paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White Paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...